Previous findings from the phase 3 DESTINY-Breast05 study (NCT04622319) showed that T-DXd demonstrated statistically significant and clinically meaningful improvement vs T-DM1 in the primary endpoint ...

Researchers assessed survival outcomes for Asian patients with newly diagnosed AML vs White patients. Researchers determined Asian patients with newly diagnosed AML may have superior OS outcomes ...

Patients with RRMM with renal impairment demonstrated similar efficacy and safety outcomes with talquetamab as those without renal impairment.

Minimal residual disease is “a credible intermediate endpoint” for some patients with newly diagnosed acute myeloid leukemia, researchers report.

Researchers sought to determine whether combination odronextamab plus CHOP would be safe and effective in patients with DLBCL. Combination odronextamab plus CHOP had promising response rates with a ...